Education
About Us
Working with TipRanks
Follow Us
Alto Neuroscience, Inc. (ANRO)
:ANRO
ANRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.60 - $15.04
Previous CloseN/A
Volume104.17K
Average Volume (3M)237.96K
Market Cap
$83.11M
Enterprise Value-$75.89M
Total Cash (Recent Filing)$160.75M
Total Debt (Recent Filing)$26.44M
Price to Earnings (P/E)―
Beta1.75
Next Earnings
Aug 19, 2025EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding27,072,128
10 Day Avg. Volume120,179
30 Day Avg. Volume237,962
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit758.90
Enterprise Value/Ebitda1.22
Forecast
1Y Price Target
$10.40Price Target Upside239.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Biomarker DevelopmentANRO is working on an EEG-machine learning-based biomarker able to predict a placebo response, which could enhance future trial outcomes.
Financial StabilityThe company's cash position of $161 million provides financial security until 2028, supporting ongoing and future research efforts.
Pipeline ExpansionThe acquisition of a dopamine combo product ALTO-207 provides another Phase II readout in 2027 for TRD depression, which presents a billion-dollar opportunity.
Bears Say
Clinical Trial ResultsMixed data on depression-related endpoints are seen as not materially de-risking future development in MDD.
Market ReactionAlto shares are trading down about 10% in response to the trial missing on conventional MDD efficacy endpoints.
Placebo ResponseA higher-than-expected placebo response was observed, and there was no significant separation between ALTO-203 and placebo in the primary outcome.
ANRO FAQ
What was Alto Neuroscience, Inc.’s price range in the past 12 months?
Alto Neuroscience, Inc. lowest stock price was $1.60 and its highest was $15.04 in the past 12 months.
What is Alto Neuroscience, Inc.’s market cap?
Alto Neuroscience, Inc.’s market cap is $83.11M.
When is Alto Neuroscience, Inc.’s upcoming earnings report date?
Alto Neuroscience, Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 11 days.
How were Alto Neuroscience, Inc.’s earnings last quarter?
Currently, no data Available
Is Alto Neuroscience, Inc. overvalued?
According to Wall Street analysts Alto Neuroscience, Inc.’s price is currently Undervalued.
Does Alto Neuroscience, Inc. pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
What is Alto Neuroscience, Inc.’s EPS estimate?
Alto Neuroscience, Inc.’s EPS estimate is -0.6.
How many shares outstanding does Alto Neuroscience, Inc. have?
Alto Neuroscience, Inc. has 27,072,128 shares outstanding.
What happened to Alto Neuroscience, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Alto Neuroscience, Inc.?
Currently, no hedge funds are holding shares in ANRO
Alto Neuroscience, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.40 (239.87% Upside)
$10.40 (239.87% Upside)
Hedge Fund Trend
Decreased
By 203.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-68.30%
12-Months-Change
Fundamentals
Return on Equity
-38.04%
Trailing 12-Months
Asset Growth
-18.11%
Trailing 12-Months
Company Description
Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.
Alto Neuroscience, Inc. (ANRO) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
ANRO Stock 12 Month Forecast
Average Price Target
$10.40
▲(239.87% Upside)
Technical Analysis
VistaGen Therapeutics
―
Jasper Therapeutics
―
Unicycive Therapeutics
―
Vigil Neuroscience Inc
―
Metagenomi, Inc.
―
Ownership Overview
8.38% Insiders
10.95% Mutual Funds
37.18% Other Institutional Investors
38.56% Public Companies and Individual Investors